Docetaxel in the community setting: An analysis of 377 breast cancer patients treated with docetaxel (Taxotere®) in the UK
- 1 February 1999
- journal article
- Published by Elsevier in Annals of Oncology
- Vol. 10 (2) , 205-210
- https://doi.org/10.1023/a:1008370930599
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer.Journal of Clinical Oncology, 1995
- Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer.Journal of Clinical Oncology, 1995
- 348 A phase II trial of docetaxel in patients (PTS) with anthracycline resistant (AR) metastatic breast cancer (MBC)European Journal Of Cancer, 1995
- Docetaxel (Taxotere): Single agent activity, development of combination treatment and reducing side-effectsCancer Treatment Reviews, 1995
- ABC of Breast Diseases: Metastatic breast cancerBMJ, 1994
- A phase II trial with Docetaxel (Taxotere™) in second line treatment with chemotherapy for advanced breast cancerAnnals of Oncology, 1994
- Multidisciplinary management of advanced primary and metastatic breast cancerCancer, 1994
- Systemic Therapy of Advanced Breast CancerDrugs, 1992